Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?-Reference-Cited by-同舟云学术

Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?

Published:2012-12-08 Issue:1 Volume:2012 Page:111-114
ISSN:1520-4391
Container-title:Hematology
language:en
Short-container-title:

Author:

Yeung David T.¹²³,Branford Susan¹³

Affiliation:

1. Department of Molecular Pathology and Centre for Cancer Biology, and

2. Department of Haematology, SA Pathology, Adelaide, Australia; and

3. Department of Medicine, University of Adelaide, Adelaide, Australia

Abstract

Abstract An 80-year-old man has newly diagnosed chronic myeloid leukemia. His BM and blood examination at diagnosis confirms chronic-phase disease, with the Philadelphia chromosome as the sole cytogenetic abnormality. He has intermediate Sokal and Hasford risk,1 and is started on imatinib 600 mg once daily. He lives 5 hours away from the nearest specialist hematology service and prefers followup with his local physician, who cannot perform BM examinations. In patients such as this, is it acceptable to monitor his therapeutic response solely with molecular studies of his peripheral blood?

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/hematology/article-pdf/2012/1/111/1500952/bep00112000111.pdf

Reference64 articles.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet;Baccarani;J Clin Oncol,2009

2. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract];Deininger;Blood (ASH Annual Meeting Abstracts),2009

3. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

4. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N Engl J Med,2010

5. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia;Kantarjian;N Engl J Med,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular monitoring in chronic myeloid leukemia—how low can you go?;Hematology;2016-12-02

2. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets;Blood;2015-02-05